keyword
MENU ▼
Read by QxMD icon Read
search

Travoprost

keyword
https://www.readbyqxmd.com/read/28617732/the-effects-of-latanoprost-with-benzalkonium-chloride-versus-travoprost-with-sofzia-on-the-ocular-surface
#1
Kamran Rahmatnejad, Christopher J Rapuano, Parul Ichhpujani, Sheryl S Wizov, Marlene R Moster, Lisa A Hark, L Jay Katz
PURPOSE: To assess ocular surface changes in participants using latanoprost with benzalkonium chloride (Xalatan) and travoprost with SofZia (Travatan Z). METHODS: In this prospective, open-label, nonrandomized cohort study, participants were classified into two groups: group 1 (n=28) naive to glaucoma therapy, group 2 (n=27) on previous Xalatan monotherapy in both eyes. Both groups started (or continued) Xalatan in the right eye and Travatan Z in the left eye. Baseline, 1-, and 2-month measurements of tear breakup time (TBUT), corneal staining score, conjunctival staining score, conjunctival hyperemia score, tear production, and intraocular pressure were obtained...
June 14, 2017: Eye & Contact Lens
https://www.readbyqxmd.com/read/28616797/the-efficacy-and-safety-of-bimatoprost-timolol-maleate-latanoprost-timolol-maleate-and-travoprost-timolol-maleate-fixed-combinations-on-24-h-iop
#2
Suzan Guven Yilmaz, Cumali Degirmenci, Yunus Emre Karakoyun, Emil Yusifov, Halil Ates
PURPOSE: To evaluate the effect of bimatoprost/timolol maleate fixed combination (BTFC), latanoprost/timolol maleate fixed combination (LTFC), and travoprost/timolol maleate fixed combination (TTFC) on 24-h intraocular pressure (IOP) in patients with open-angle glaucoma. METHODS: This prospective, observer-masked, randomized study included 50 patients with primary open-angle glaucoma. All patients were using hypotensive lipids and timolol maleate fixed combination treatment for ≥4 weeks and had an IOP ≤ 21 mmHg...
June 14, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28458346/blood-pressure-elevation-associated-with-topical-prostaglandin-f2%C3%AE-analogs-an-analysis-of-the-different-spontaneous-adverse-event-report-databases
#3
Katsuhiro Ohyama, Haruna Kawakami, Michiko Inoue
Topical prostaglandin F2α (PGF2α) analogs are widely used as the first line of therapy for glaucoma. Systemic PGF2α is suggested to increase blood pressure. Some ophthalmic formulations with β-receptor blocking or α-receptor stimulating actions are reported to cause systemic adverse events such as a decrease in heart rate and blood pressure. The objective of this study was to evaluate the association between topical PGF2α analogs and blood pressure elevation. We analyzed the reports obtained from the Food and Drug Administration Adverse Event Reporting System (FAERS) database from the first quarter of 2004 until the end of 2015 and the Japanese Adverse Drug Event Report (JADER) database from April 2004 to January 2016 for signal detection using reporting odds ratio (ROR), a method of disproportionality analyses...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28437175/pharmacokinetics-and-safety-of-travoprost-0-004-ophthalmic-solution-preserved-with-polyquad-in-pediatric-patients-with-glaucoma
#4
Erin Stahl, Dominique Bremond-Gignac, Theresa Landry, Mike Curtis, Kinfemichael Gedif, Sami Al Shahwan, El Roy Dixon
PURPOSE: To evaluate the systemic pharmacokinetics (PKs) of travoprost 0.004% preserved with Polyquad(®) (TRAVATAN(®)) in pediatric patients with glaucoma or ocular hypertension. METHODS: This was a phase 1, open-label, multicenter clinical study of patients aged ≥2 months to <18 years. Patients received daily administration of travoprost 0.004% preserved with Polyquad in both eyes for 7 days. Plasma samples were collected 30 min before the final dose and at 10, 20, 40, and 80 min postdose...
June 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28384377/implantation-of-two-second-generation-trabecular-micro-bypass-stents-and-topical-travoprost-in-open-angle-glaucoma-not-controlled-on-two-preoperative-medications-18-month-follow-up
#5
John Berdahl, Lilit Voskanyan, Jonathan S Myers, Dana M Hornbeak, Jane Ellen Giamporcaro, L Jay Katz, Thomas W Samuelson
IMPORTANCE: Additional data are sought regarding treatment options for glaucoma, a major cause of global blindness. BACKGROUND: The study assessed outcomes following standalone implantation of 2 second-generation trabecular micro-bypass stents and postoperative topical prostaglandin in eyes with open-angle glaucoma (OAG) not controlled on 2 preoperative medications. DESIGN: Prospective, nonrandomized, open-label study at a tertiary-care ophthalmology centre...
April 6, 2017: Clinical & Experimental Ophthalmology
https://www.readbyqxmd.com/read/28379653/factors-related-to-prostaglandin-associated-periorbitopathy-in-glaucoma-patients
#6
Chanikarn Patradul, Visanee Tantisevi, Anita Manassakorn
PURPOSE: To determine factors related to prostaglandin-associated periorbitopathy (PAP) and its prevalence in glaucoma or ocular hypertension (OHT) patients using prostaglandins analogs (PGAs). DESIGN: A cross-sectional study. METHODS: A study of glaucoma or OHT patients, using topical PGAs for at least 3 months, was performed. Eyes treated with PGAs were photoraphed and independently evaluated for PAP by 2 glaucoma specialists using at least 4 out of 7 clinical appearances...
May 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/28352151/efficacy-of-two-trabecular-micro-bypass-stents-combined-with-topical-travoprost-in-open-angle-glaucoma-not-controlled-on-two-preoperative-medications-3-year-follow-up
#7
David F Chang, Eric D Donnenfeld, L Jay Katz, Lilit Voskanyan, Iqbal Ike K Ahmed, Thomas W Samuelson, Jane Ellen Giamporcaro, Dana M Hornbeak, Kerry D Solomon
PURPOSE: To evaluate the long-term intraocular pressure (IOP)-lowering effect and safety parameters following treatment with two trabecular micro-bypass stents and topical prostaglandin in phakic eyes with open-angle glaucoma (OAG) not controlled on two preoperative medications. METHODS: This prospective, single-arm, unmasked study enrolled 39 qualified phakic eyes with OAG not controlled on 2 medications, preoperative medicated IOP of 18-30 mmHg, and IOP following medication washout of 22-38 mmHg...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28239491/efficacy-and-tolerability-of-travoprost-0-004-timolol-0-5-fixed-dose-combination-for-the-treatment-of-primary-open-angle-glaucoma-or-ocular-hypertension-inadequately-controlled-with-beta-blocker-monotherapy
#8
Simon Fabian Lerner, Ki Ho Park, Douglas A Hubatsch, Valeriy Erichev, Jose A Paczka, Timothy V Roberts
Objective. To evaluate the efficacy and tolerability of travoprost 0.004%/timolol 0.5% fixed-dose combination (TTFC) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) inadequately controlled on beta-blocker monotherapy. Methods. In this phase IV, open-label study, 156 patients on beta-blocker monotherapy with mean intraocular pressure (IOP) between 18 and 32 mmHg were randomized (no washout period) to receive TTFC for 8 weeks (TTFC group) or to continue beta-blocker monotherapy for 4 weeks followed by TTFC for the remaining 4 weeks (beta-blocker group)...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28178150/the-effects-of-selective-laser-trabeculoplasty-and-travoprost-on-circadian-intraocular-pressure-fluctuations-a-randomized-clinical-trial
#9
RANDOMIZED CONTROLLED TRIAL
Weerawat Kiddee, Supreeya Atthavuttisilp
BACKGROUND: To compare the effect of selective laser trabeculoplasty (SLT) and travoprost on 24-hour IOP fluctuations in primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG). METHODS: Sixty eyes were included. Sixteen and 14 eyes of POAG patients were randomized to receive 360° SLT or 0.004% travoprost, respectively. Fourteen and 16 eyes of NTG patients were randomized to receive either SLT or travoprost, respectively. The 24-hour IOP data were collected before treatment and 6 to 8 weeks after treatment...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28146132/a-novel-convergent-synthesis-of-the-potent-antiglaucoma-agent-tafluprost
#10
Małgorzata Krupa, Michał Chodyński, Anna Ostaszewska, Piotr Cmoch, Iwona Dams
Tafluprost (AFP-168, 5) is a unique 15-deoxy-15,15-difluoro-16-phenoxy prostaglandin F2α (PGF2α) analog used as an efficacious ocular hypotensive agent in the treatment of glaucoma and ocular hypertension, as monotherapy, or as adjunctive therapy to β-blockers. A novel convergent synthesis of 5 was developed employing Julia-Lythgoe olefination of the structurally advanced prostaglandin phenylsulfone 16, also successfully applied for manufacturing of pharmaceutical grade latanoprost (2), travoprost (3) and bimatoprost (4), with an aldehyde ω-chain synthon 17...
January 31, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28053501/fixed-combination-of-travoprost-and-timolol-maleate-reduces-intraocular-pressure-in-japanese-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension-analysis-by-prostaglandin-analogue
#11
Tadashi Nakano, Shiro Mizoue, Nobuo Fuse, Aiko Iwase, Shun Matsumoto, Keiji Yoshikawa
BACKGROUND: We have shown a decrease in mean intraocular pressure (IOP) by switching to travoprost/timolol fixed combination (TTFC) in subjects receiving prostaglandin analogue (PGA) monotherapy and requiring additional medication in a previous report. For analyzing factors affecting IOP reduction, baseline IOP and preceding PGA were selected as statistically and clinically significant factors. In this report, we examine IOP-lowering effect and adverse drug reactions by preceding PGA...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27993589/adherence-to-fixed-combination-versus-unfixed-travoprost-0-004-timolol-0-5-for-glaucoma-or-ocular-hypertension-a%C3%A2-randomized-trial
#12
RANDOMIZED CONTROLLED TRIAL
Howard S Barnebey, Alan L Robin
PURPOSE: To assess adherence to treatment with fixed-combination travoprost 0.004%/timolol 0.5% (TTFC) compared with separate containers of travoprost 0.004% and timolol 0.5% (TRAV+TIM; unfixed) using electronic dosing aids. DESIGN: Randomized, controlled, observer-masked clinical trial. METHODS: setting: Two US clinical sites. PATIENT POPULATION: Eligible patients were adults diagnosed with open-angle glaucoma or ocular hypertension...
April 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/27822015/impossibility-to-eliminate-observer-effect-in-the-assessment-of-adherence-in-clinical-trials
#13
Jonathan S Myers, Scott J Fudemberg, Robert E Fintelmann, Lisa A Hark, Nitasha Khanna, Benjamin E Leiby, Michael Waisbourd
PURPOSE: To utilize the Travoprost Dosing Aid (DA) in the assessment of patient medication adherence, while also determining whether or not altering the functionality of the DA in three randomized subject groups can reduce observer effect. METHODS: Forty-five subjects were randomized into three groups: two with monitored DAs and one without monitoring. One group of subjects was given a DA that both monitored drop usage and had visual and audible alarms, while the other monitored group included subjects given a DA that had no alarms but continued to monitor drop usage...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27799736/efficacy-and-tolerability-of-benzalkonium-chloride-free-travoprost-in-glaucoma-patients-switched-from-benzalkonium-chloride-preserved-latanoprost-or-bimatoprost
#14
Julian García-Feijoo, Francisco J Muñoz-Negrete, Douglas A Hubatsch, Gemma C Rossi
INTRODUCTION: The preservative benzalkonium chloride (BAK) is used to preserve several topical, intraocular pressure (IOP)-lowering glaucoma medications but can cause tolerability concerns that may lead to decreased adherence to treatment and ultimately diminish the effectiveness of IOP control. The study aimed to determine the efficacy and tolerability of BAK-free travoprost preserved with polyquaternium-1 in glaucoma patients switched from BAK-preserved latanoprost or bimatoprost. METHODS: This 12-week, open-label study was conducted in Europe between December 2011 and February 2013...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27764023/sustained-drug-delivery-for-glaucoma-current-data-and-future-trends
#15
REVIEW
Ahmad A Aref
PURPOSE OF REVIEW: Sustained drug delivery has been recognized as a need for patients with ocular hypertension or glaucomatous optic neuropathy. Several sustained drug delivery systems and devices are currently on the horizon. This review aims to summarize initial results with these platforms, as reported in the literature, and also provide insight into their possible role in the glaucoma treatment paradigm. RECENT FINDINGS: Sustained drug delivery systems currently on the horizon include the topical bimatoprost ocular insert, travoprost and latanoprost punctal plugs, latanoprost-eluting contact lenses, bimatoprost and travoprost intraocular implants, as well as several other therapies in earlier stages of development...
March 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/27633513/tolerability-and-efficacy-of-bimatoprost-0-01%C3%A2-in-patients-with-open-angle-glaucoma-or-ocular-hypertension-evaluated-in-the-taiwanese-clinical-setting-the-asia-pacific-patterns-from-early-access-of-lumigan-0-01%C3%A2-appeal-taiwan-study
#16
MULTICENTER STUDY
Ying Ying Chen, Tsing-Hong Wang, Catherine Liu, Kwou-Yeung Wu, Shin-Lin Chiu, Susan Simonyi, Da-Wen Lu
BACKGROUND: In randomized, controlled trials of open-angle glaucoma (OAG) or ocular hypertension (OHT), bimatoprost 0.01 % improved tolerability while retaining the intraocular pressure (IOP)-lowering efficacy of bimatoprost 0.03 %. Given geographic/racial differences in glaucoma presentation, the APPEAL study assessed the occurrence and severity of hyperemia produced by bimatoprost 0.01 %, and its efficacy, in the Taiwanese clinical setting. METHODS: In this multicenter, open-label, observational study, treatment-naïve and previously treated patients with OHT or OAG received once-daily bimatoprost 0...
September 15, 2016: BMC Ophthalmology
https://www.readbyqxmd.com/read/27619225/newly-diagnosed-primary-open-angle-glaucoma-randomized-to-2-trabecular-bypass-stents-or-prostaglandin-outcomes-through-36-months
#17
Steven D Vold, Lilit Voskanyan, Manfred Tetz, Gerd Auffarth, Imran Masood, Leon Au, Iqbal Ike K Ahmed, Hady Saheb
PURPOSE: To examine outcomes through 36 months in phakic eyes with newly diagnosed primary open-angle glaucoma (POAG) naïve to therapy randomized to treatment with two trabecular micro-bypass stents or topical prostaglandin. METHODS: Subjects with POAG naïve to therapy, with intraocular pressure (IOP) ≥21 and ≤40 mmHg, were randomized to implantation of two stents or travoprost. Additional medication was to be prescribed post-treatment for elevated IOP or glaucomatous optic nerve findings...
December 2016: Ophthalmology and Therapy
https://www.readbyqxmd.com/read/27612621/prolonged-ocular-inflammation-in-endotoxin-induced-uveitis-in-lysosomal-phospholipase-a2-deficient-mice
#18
Kanako Sawada, Miki Hiraoka, Akira Abe, Robert Kelly, James A Shayman, Hiroshi Ohguro
PURPOSE: The goal of present study was to elucidate the pathophysiological roles of lysosomal phospholipase A2 (LPLA2) in intraocular pressure (IOP) levels and ocular inflammation. METHODS: C57BL/6 (wild-type) and LPLA2-deficient mice with C57BL/6 background were employed. The IOPs were compared between wild-type and LPLA2-deficient mice during their aging, after topical administration of antiglaucoma medications such as travoprost, dorzolamide, or timolol maleate, or after induction of endotoxin-induced uveitis (EIU) using lipopolysaccharide (LPS)...
September 9, 2016: Current Eye Research
https://www.readbyqxmd.com/read/27536047/evaluation-of-physical-properties-of-generic-and-branded-travoprost-formulations
#19
REVIEW
Meenakshi Wadhwani, Sanjay K Mishra, Dewang Angmo, Thirumurthy Velpandian, Ramanjit Sihota, Ankita Kotnala, Shibal Bhartiya, Tanuj Dada
PURPOSE: Comparative evaluation of pharmaceutical characteristics of three marketed generic vs branded travoprost formulations. MATERIALS AND METHODS: Three generic travoprost formulations and one branded (Travatan without benzalkonium chloride) formulation (10 vials each), obtained from authorized agents from the respective companies and having the same batch number, were used. These formulations were coded and labels were removed. At a standardized room temperature of 25°C, the drop size, pH, relative viscosity, and total drops per vial were determined for Travatan (Alcon, Fort Worth, TX, USA) and all the generic formulations...
May 2016: Journal of Current Glaucoma Practice
https://www.readbyqxmd.com/read/27506567/does-the-intraocular-pressure-lowering-effect-of-prostaglandin-analogues-continue-over-the-long-term
#20
Caner Kara, Emine Malkoç Şen, Kadriye Ufuk Elgin, Kurtuluş Serdar, Pelin Yilmazbaş
The purpose of the study is to assess the changes in the long-term effects of prostaglandin analogues (PGAs) on intraocular pressure (IOP) reduction in patients with primary open-angle glaucoma (POAG). Data of POAG patients treated with latanoprost (0.005 %), travoprost (0.004 %), or bimatoprost (0.03 %) as the first line treatment for 5 years or more were retrospectively evaluated. Baseline ophthalmic assessment values were recorded together with the IOP at the 6th month, 1st year, and then annually. The 79 patients included 33 (41...
August 9, 2016: International Ophthalmology
keyword
keyword
96072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"